Oligosaccharyltransferase (OST) complex inhibition effectively treats rodent and human prions
PLOS Pathogens · 2026
DOI: 10.1371/journal.ppat.1013867 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2026. Verfasst von Kathryn S Beauchemin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, United States of America. Hauptthemen laut MEDLINE: Hexosyltransferases, Membrane Proteins, Prion Diseases, Prions. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 98 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC0). Gefördert von: NIGMS NIH HHS, NIAID NIH HHS, NINDS NIH HHS.
Abstract (Originalsprache)
Prion diseases are invariably fatal neurodegenerative diseases that occur when the prion protein misfolds into a pathogenic form. There are currently no clinical treatments or cures for prion disease. Current challenges in the development of prion therapeutics include prion strain specificity, which can cause the emergence of drug-resistant prions, and lack of efficacy in treating human prions despite promising results in rodent models. Here we identify a novel therapeutic target for prion disease: the oligosaccharyltransferase (OST) complex. The OST complex is responsible for transferring the mature glycan to the acceptor polypeptide during N-glycosylation. We found that inhibiting OST effectively treats rodent prions in various dividing and non-dividing cell types. Importantly, we also demonstrate efficacy in treating human sCJD prions in non-dividing cerebral organoids. Inhibition of OST results in a 50% reduction in cell surface expression of the prion protein, PrP C . In addition, lysates of cells treated with the OST inhibitor NGI-1 were unable to amplify PrP Sc seeds in Protein Misfolding Cyclic Amplification (PMCA) reactions. In summary, our results identify OST as a novel therapeutic target that regulates both the abundance of cell surface PrP C as well as its ability to convert into multiple strains of PrP Sc , including human prions, in various in vitro systems.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, United States of America.
- Prion Cell Biology Section, Laboratory of Neurological Infections and Immunity, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, Montana, Unite…
- Department of Medicine, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, United States of America.
ORCID-Profile: Surachai Supattapone
Förderung
- NIGMS NIH HHS
- NIAID NIH HHS
- NINDS NIH HHS
- National Institute of Neurological Disorders and Stroke
- National Institute of General Medical Sciences
- National Institutes of Health
Zitieren
APA
Beauchemin, K. S., Kun, J., Groveman, B., Williams, K., Salerno, F., Francomacaro, L. M., Robison, P., Haigh, C. L., & Supattapone, S. (2026). Oligosaccharyltransferase (OST) complex inhibition effectively treats rodent and human prions. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1013867
Vancouver
Beauchemin KS, Kun J, Groveman B, Williams K, Salerno F, Francomacaro LM, et al. Oligosaccharyltransferase (OST) complex inhibition effectively treats rodent and human prions. PLOS Pathogens. 2026. doi:10.1371/journal.ppat.1013867
BibTeX
@article{Beauchemin2026,
author = {Beauchemin, Kathryn S and Kun, Judit and Groveman, Bradley and Williams, Katie and Salerno, Francesca and Francomacaro, Lisa M and Robison, Patrick and Haigh, Cathryn L and Supattapone, Surachai},
title = {Oligosaccharyltransferase (OST) complex inhibition effectively treats rodent and human prions},
journal = {PLOS Pathogens},
year = {2026},
doi = {10.1371/journal.ppat.1013867}
}
EUVIMED